Indication Optimisation

Company wished to develop a novel Phase I pain compound globally in the most commercially-viable initial indication and optimise subsequent launch sequence

Analysed current treatment pricing and reimbursement, development pipeline, as well as real-world evidence around unmet need and treatments patterns in over 10 different possible indications to determine initial indication with greatest value. Validated assumptions with external payers, KOLs, and regulatory bodies, as well as internal experts. Recommended life-cycle management opportunities post initial launch

Obtained buy-in from internal stakeholders across regions and aligned organisation around the lead indication and optimal development pathway